SG Americas Securities’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

SG Americas Securities’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-22,321	Closed	-$2.4M	–	3433
2023 Q1	$2.4M	Buy	22,321 +10,214	+84%	+$1.18M	0.03%	571
2022 Q4	$1.33M	Buy	12,107 +5,544	+84%	+$360K	0.02%	787
2022 Q3	$387K	Buy	+6,563	New	+$300K	﹤0.01%	1773
2022 Q1	–	Sell	-7,659	Closed	-$303K	–	3599
2021 Q4	$303K	Buy	7,659 +1,263	+20%	+$39.5K	﹤0.01%	2438
2021 Q3	$152K	Buy	+6,396	New	+$151K	﹤0.01%	3431

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

SG Americas Securities's RXDX Position: Q2 2023 in Review

SG Americas Securities sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 22,321 shares — an estimated $2.4M sold.

SG Americas Securities first reported a position in RXDX in Q3 2021 and held it in 5 quarters. The position peaked at $2.4M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

SG Americas Securities reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
SG Americas Securities sold 22,321 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $2.4M.
SG Americas Securities first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2021 and held it in 5 quarters.
SG Americas Securities's Prometheus Biosciences, Inc. Common Stock position peaked at $2.4M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on SG Americas Securities's 13F filing for Q2 2023, filed 10 Jul 2023.